Current Report · Items 8.01, 9.01 · 8-K

Alto Neuroscience Inc.

ANRONYSEEQUITYCurrent

Other Events

Item 8.01 Other Events. On April 1, 2026, Alto Neuroscience, Inc. issued a press release entitled “Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Filed Apr 1, 2026Accepted Apr 1, 2026, 4:55 PM EDTCIK 1999480Accession 0001104659-26-038593

View company →Permanent SEC source ↗

Company context

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Current securities

ANRONYSE · EQUITY · Current

Recent company filings

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Filed exhibits (1)

EX-99.1 (by filename) tm2610746d1_ex99-1.htm

EX-99.1 2 tm2610746d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) - - Alto has developed a modified-release, once-daily oral formulation of ALTO-101; the Company plans to explore partnering opportunities for this formulation - - Development of ALTO-207 remains the top priority for the Company; Phase 2b on track to initiate in 1H 2026 - MOUNTAIN VIEW, Calif., April 1, 2026 - Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization. ALTO-101 did not achieve statistical significance on primary electroencephalography (EEG) or cog…

Open exhibit ↗

Get the free weekly BCS email.